AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Uridylate-specific endoribonuclease

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P21128

UPID:

ENDOU_HUMAN

Alternative names:

Placental protein 11; Protein endoU

Alternative UPACC:

P21128; B2RBJ3; B3KQS7; B7Z6E1; Q2NKJ4

Background:

Uridylate-specific endoribonuclease, also known as Placental protein 11 or Protein endoU, is a pivotal enzyme that specializes in cleaving single-stranded RNAs. It targets uridylates, favoring UU and GU sites over CU and AU, to release products with a 2',3'-cyclic phosphate at the 3'-end. This specificity underscores its unique role in RNA metabolism.

Therapeutic significance:

Understanding the role of Uridylate-specific endoribonuclease could open doors to potential therapeutic strategies. Its precise function in RNA processing not only highlights its importance in cellular biology but also suggests avenues for drug discovery targeting RNA-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.